Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells

Elda Tagliabue, Cristina Ghirelli, Paolo Squicciarini, Pierangela Aiello, Maria Ines Colnaghi, Sylvie Ménard

Research output: Contribution to journalArticle

Abstract

Immunocytochemical analysis of breast carcinoma specimens for α6β4 integrin expression and other different pathobiological markers revealed β4 integrin subunit expression in 36 of 80 cases analyzed and a significant association only with α6 integrin subunit expression (P <0.01) and laminin production (P = 0.01) by tumor cells. Survival analysis indicated that β4 and α6 expression are associated with poor prognosis (P = 0.02), whereas laminin production showed only borderline association (P = 0.06). However, analysis of disease outcome in relation to expression of both α6β4 and laminin indicated best outcomes for patients with tumors producing laminin but not expressing α6β4 integrin, whereas worst outcomes were observed for α6β4- and laminin-positive tumors, indicating that α6β4 expression was associated with prognosis, mainly in the laminin-producing tumor subset. These data indicate that the prognostic value of α6β4 integrin expression is affected by laminin production from tumor cells and suggest that interaction between these two molecules mediates distinct signals that are important for tumor progression.

Original languageEnglish
Pages (from-to)407-410
Number of pages4
JournalClinical Cancer Research
Volume4
Issue number2
Publication statusPublished - Feb 1998

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells'. Together they form a unique fingerprint.

  • Cite this

    Tagliabue, E., Ghirelli, C., Squicciarini, P., Aiello, P., Colnaghi, M. I., & Ménard, S. (1998). Prognostic value of α6β4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. Clinical Cancer Research, 4(2), 407-410.